Mylan Reports 25 Percent Drop in Q3 Net Earnings

Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82

  • 2013 Adjusted Diluted EPS Guidance Range Narrowed to $2.80 – $2.90
  • Reiterates 2014 Targets of 12% Growth in Revenues and 19% Growth in Adjusted Diluted EPS
  • Board of Directors Authorizes Share Repurchase of Up to $500 Million
  • Expects to Close Agila Transaction in the Fourth Quarter of 2013


PITTSBURGH, Oct. 31, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2013.

Read the source article at Pharmalive

About the Author

Leave a Reply